Rua’s Australian Supplier, Cann Group, Receives GMP Certification for Southern Facility

Rua Bioscience is pleased to share that Cann Group has been granted a GMP licence to manufacture therapeutic goods for its Southern facility (Southern GMP Licence) by Australia’s Therapeutic Goods Administration (TGA).

The Southern GMP licence enables Cann to manufacture Active Pharmaceutical Ingredient (API) and medicinal cannabis products under GMP conditions for Australian and overseas customers, following a substantial upgrade of its facilities.

Rua Bioscience CEO, Rob Mitchell says, “this is great news for Cann Group and a critical regulatory milestone that will enable future supply for Rua as a result of the Zalm acquisition.”

With Shareholders having approved the Rua purchase of Zalm, Rua has acquired Zalm’s third party supply contract for GMP-grade medicinal cannabis with Cann, including exclusive supply into New Zealand.

Cann is also in the final commissioning phase of one of Australasia’s most technologically advanced indoor growing facilities at Mildura, Victoria, which will help Rua achieve world world-class and globally-competitive scale. When the first stage of this facility is fully commissioned, Cann expects to have capacity to produce 12,500kg of medicinal cannabis per annum. Cann has the ability to increase this to 70,000kg in future stages, creating one of the largest facilities in Australasia.